Advertisement

Stability-indicating methods for determination of hydrochlorothiazide in combination with some antihypertensive drugs in the presence of its main impurities

  • Maissa Y. Salem
  • Nagiba Y. Hassan
  • Yasmin M. Fayez
  • Samah A. Sabour
  • Enas S. AliEmail author
Original Paper
  • 22 Downloads

Abstract

Hydrochlorothiazide (HCTZ) is potent diuretic that used alone or in combination with other antihypertensive drugs such as labetalol hydrochloride (Lab) or nebivolol hydrochloride (Neb) to control moderate to severe hypertension. As there is no published method for simultaneous determination of HCTZ and Lab (mixture Ι) or Neb (mixture ΙΙ) in pharmaceutical formulations in presence of HCTZ-related impurities, it was important to develop validated stability-indicating HPLC methods for analysis of these mixtures in quality control laboratories. These methods based on gradient RP-HPLC separation of mixture Ι at 215 nm using acetonitrile:0.1% triethylamine pH = 2 (12:88 v/v) as mobile phase at flow rate 1.0 mL/min using Promosil C18 (150 mm × 4.6 mm i.d.; 5 µm) column. While mixture ΙΙ separation was performed at 220 nm using BDS Hypersil C18 (250 mm × 4.6 mm i.d.; 5 µm) column with mobile phase of acetonitrile:phosphate buffer pH = 3 (15:85 v/v) at flow rate 1.0 mL/min. The responses were linear over concentration ranges 2.0–100 µg/mL (r = 0.9997) and 1.0–100 µg/mL (r = 0.9998) with mean recoveries 100.16% and 100.43% of Lab and HCTZ, respectively meanwhile 5.0–100 µg/mL (r = 0.9997) and 2.0–100 µg/mL (r = 0.9996) with mean recoveries 99.99% and 100.63% of Neb and HCTZ, respectively. Methods were validated according to ICH guidelines; the results were statistically compared with the company methods and there was no significant difference. The proposed methods have the advantages of being stability-indicating and time saving with low solvent consumption which favors their usage in quality control routine analysis of selected mixtures in their pharmaceutical formulations.

Keywords

Chromatography Hydrochlorothiazide Impurities Labetalol hydrochloride Nebivolol hydrochloride 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest, financial or otherwise.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

13738_2019_1593_MOESM1_ESM.doc (610 kb)
Supplementary material 1 (DOC 611 KB)

References

  1. 1.
    N.As. Joel, C. Shantaram, I.J. Naresh, Res. Pharm. Biomed. Sci. 4, 380–384 (2013).  https://doi.org/10.13179/canchemtrans.2013.01.01.0014 Google Scholar
  2. 2.
    D.R. El-Wasseef, S.M. El-Ashry, M.A. Abu-El-Enein, M.A.A. Moustafa, J. Food Drug Anal. 14, 133–140 (2006).  https://doi.org/10.6227/jfda Google Scholar
  3. 3.
    F. Belal, S. Al-Shaboury, A.S. Al-Tamrah, J. Pharm. Biomed. Anal. 30, 1191–1196 (2002).  https://doi.org/10.1016/S0731-7085(02)00471-5 CrossRefGoogle Scholar
  4. 4.
    N. Rahman, S.K. Haque, Int. J. Biomed. Anal. 4, 140–146 (2008)Google Scholar
  5. 5.
    M. Delamoye, C. Duvernewil, F. Paraire, P. de Mazancourt, J.C. Alvarez, Int. Forensic Sci. 141, 23–31 (2004).  https://doi.org/10.1016/j.forsciint.2003.12.008 CrossRefGoogle Scholar
  6. 6.
    C. Karlsson, H. Wikstrom, D.D. Armstrong, P.K. Owens, J. Chromatogr. A. 897, 349–363 (2000).  https://doi.org/10.1016/S0021-9673(00)00805-0 CrossRefGoogle Scholar
  7. 7.
    A. Witek, H. Hopkala, G. Matysik, Chromatographia 50, 41–44 (1999).  https://doi.org/10.1007/BF02493615 CrossRefGoogle Scholar
  8. 8.
    S. Carda-Broch, R. Rapado-Martinez, I. Esteve-Romero, M.C. Garcia-Alverez-Coque, J. Chromatogr. Sci. 37, 93–102 (1999).  https://doi.org/10.1093/chromsci/37.4.93 CrossRefGoogle Scholar
  9. 9.
    T.V. Goel, J.G. Nikelly, R.C. Simpson, B.K. Matuszewski, J. Chromatogr. A 7, 213–221 (2004).  https://doi.org/10.1016/j.chroma.2003.08.082 CrossRefGoogle Scholar
  10. 10.
    S.L. Tamisier-Karolak, M.A. Stenger, A. Bommart, Electrophoresis 20, 2656–2663 (1999).  https://doi.org/10.1002/(SICI)1522-2683(19990901)20:13%3C2656::AID-ELPS2656%3E3.0.CO;2-6 CrossRefGoogle Scholar
  11. 11.
    S. Jana, P. Jozef, J. Chromatogr. A 735, 403–408 (1996).  https://doi.org/10.1016/0021-9673(95)00722-9 CrossRefGoogle Scholar
  12. 12.
    M.A. Iorio, A. Mazzeo-Farina, A. Doldo, J. Pharm. Biomed. Anal. 5, 1–10 (1987).  https://doi.org/10.1016/0731-7085(87)80002-X CrossRefGoogle Scholar
  13. 13.
    E. Gorodkiewicz, P. Falkowski, A. Sankiewicz, Z. Figaszewski, J. Chem. 1, 242–259 (2003).  https://doi.org/10.2478/BF02476227 Google Scholar
  14. 14.
    A. Radi, Z. El-Sherif, A. Wassel, Chem. Papers 58, 242–246 (2004)Google Scholar
  15. 15.
    A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (eds.), The Pharmacological Basis of Therapeutics, 8th edn. (Pergamon Press, Oxford, 1990), p. 847Google Scholar
  16. 16.
    Y. Gupta, A. shrivastava, D. Duggal, A. Patel, S. Agrawal, J. Young Pharm. 1, 264–269 (2009).  https://doi.org/10.4103/0975-1483.57078 CrossRefGoogle Scholar
  17. 17.
    A. Manzoor, Y.N. Manohara, M.C. Ravi, Int. J. Chem. Tech. Res. 4, 328–336 (2012)Google Scholar
  18. 18.
    S.A. Patel, H.M. Patel, Int. J. PFR 2, 28–38 (2012)Google Scholar
  19. 19.
    K.V. Shah, P.R. Tirgar, D.B. Sheth, T.R. Desai, Int. J. Pharm. Sci. 2, 27–35 (2011)Google Scholar
  20. 20.
    R.K. Patel, J.B. Patel, Int. J. APBC. 1, 496–502 (2012)Google Scholar
  21. 21.
    S.C. Sweetman, B. Pharm, F.R. Pharm, S. Martindale, The Complete Drug Reference, 36th edn. (The Pharmaceutical Press, London, 2009), pp. 1307–1311Google Scholar
  22. 22.
    D. Ivanović, M. Medenica, B. Jančić, N. Knežević, A. Malenović, J. Milić, Acta Chromatogr. 18, 143–156 (2007)Google Scholar
  23. 23.
    M.A. Hegazy, F.H. Metwaly, M. Abdelkawy, N.S. Abdelwahab, J. Chromatogr. Sci. 49, 129–135 (2011).  https://doi.org/10.1093/chrsci/49.2.129 CrossRefGoogle Scholar
  24. 24.
    A.T. Hemke, M.V. Bhure, K.S. Chouhan, K.R. Gupta, S.G. Wadodkar, ECHEM 7, 1156–1161 (2010)Google Scholar
  25. 25.
    C. Vetuschi, A. Giannandrea, G. Carlucci, P. Mazzeo, Farmaco 60, 665–670 (2005).  https://doi.org/10.1016/j.farmac.2005.04.013 CrossRefGoogle Scholar
  26. 26.
    M.E. Martin, O.M. Hernandez, A.I. Jimenez, J.J. Arias, F. Jimenez, Anal. Chim. Acta 381, 247–256 (1999).  https://doi.org/10.1016/S0003-2670(98)00732-6 CrossRefGoogle Scholar
  27. 27.
    U.S. Pharmacopoeia 40th edn. (U.S. Pharmacopeial Convention, Inc., Rockville, 2017)Google Scholar
  28. 28.
    ICH Validation of analytical procedures: text and methodology Q2 (R1), in International Conference on Harmonization (2005)Google Scholar

Copyright information

© Iranian Chemical Society 2019

Authors and Affiliations

  • Maissa Y. Salem
    • 1
  • Nagiba Y. Hassan
    • 1
  • Yasmin M. Fayez
    • 1
  • Samah A. Sabour
    • 2
  • Enas S. Ali
    • 2
    Email author
  1. 1.Analytical Chemistry Department, Faculty of PharmacyCairo UniversityCairoEgypt
  2. 2.National Organization for Drug Control and Research (NODCAR)DokkiEgypt

Personalised recommendations